Validation of Insulin Protocol for Prevention and Management of Hyperglycemia in Oncology Patients With Diabetes Receiving High Dose Glucocorticoid Therapy

NCT02012465 EARLY_PHASE1 COMPLETED

There are no guidelines for the management of glucocorticoid- (henceforth steroid) induced elevated blood sugars (henceforth hyperglycemia). Oncology ward patients have particularly high rates of hyperglycemia and are frequently exposed to high dose steroid therapy. A prior study by Muthala et al. (unpublished data) found a relationship between insulin requirements needed to maintain normal blood sugars, patient weight, and mg of steroid administered. In this pilot study, through an endocrine consult team, a weight-based, steroid dose-based insulin protocol will be implemented for the management of hyperglycemia in lymphoma patients requiring high dose steroid therapy, with the goal of reducing hyperglycemia incidence.

Details

Lead sponsor	Washington University School of Medicine
Phase	EARLY_PHASE1
Status	COMPLETED
Enrolment	15
Start date	2013-09
Completion	2015-05

Conditions

• Lymphoma
• Diabetes Mellitus, Type 2
• Hyperglycemia

Interventions

• Insulin protocol

Primary outcomes

• Incidence of hyperglycemia — up to 5 days of hospital course
  Defined as blood glucose \> 180 mg/dL. This will be measured as the % of patient-days with a blood sugar \> 180 mg/dL.

Countries

United States